Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew H Limper

Showing results (101-110 of 231) with videos related to

Pageof 24
Sort By:
Drugs in R&D|April 29, 2022
Preclinical and Toxicology Studies of BRD5529, a Selective Inhibitor of CARD9Theodore J Kottom, Kyle Schaefbauer, Eva M Carmona, et al.
Infection and Immunity|April 29, 2015
Evidence for Proinflammatory β-1,6 Glucans in the Pneumocystis carinii Cell WallTheodore J Kottom, Deanne M Hebrink, Paige E Jenson, et al.
Infection and Immunity|October 24, 2003
Lung epithelial cells and extracellular matrix components induce expression of Pneumocystis carinii STE20, a gene complementing the mating and pseudohyphal growth defects of STE20 mutant yeastTheodore J Kottom, Julia R Köhler, Charles F Thomas, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 1, 2015
β-Glucan-Activated Human B Lymphocytes Participate in Innate Immune Responses by Releasing Proinflammatory Cytokines and Stimulating Neutrophil ChemotaxisMohamed F Ali, Christopher B Driscoll, Paula R Walters, et al.
Annals of the American Thoracic Society|January 19, 2021
Adoption of the Antifibrotic Medications Pirfenidone and Nintedanib for Patients with Idiopathic Pulmonary FibrosisTimothy M Dempsey, Stephanie Payne, Lindsey Sangaralingham, et al.
Infection and Immunity|March 26, 2003
Surfactant protein D-mediated aggregation of Pneumocystis carinii impairs phagocytosis by alveolar macrophagesSuk-Joong Yong, Zvezdana Vuk-Pavlovic, Joseph E Standing, et al.
American Journal of Respiratory and Critical Care Medicine|June 1, 2019
Clinical Effectiveness of Antifibrotic Medications for Idiopathic Pulmonary FibrosisTimothy M Dempsey, Lindsey R Sangaralingham, Xiaoxi Yao, et al.
American Journal of Respiratory Cell and Molecular Biology|September 16, 2016
Characterization of N-Acetylglucosamine Biosynthesis in Pneumocystis species. A New Potential Target for TherapyTheodore J Kottom, Deanne M Hebrink, Paige E Jenson, et al.
International Journal of Dermatology|March 25, 2016
Pneumocystis jiroveci pneumonia in patients treated with systemic immunosuppressive agents for dermatologic conditions: a systematic review with recommendations for prophylaxisTania M Gonzalez Santiago, David A Wetter, Amer N Kalaaji, et al.
American Journal of Respiratory and Critical Care Medicine|December 17, 2009
Imatinib treatment for idiopathic pulmonary fibrosis: Randomized placebo-controlled trial resultsCraig E Daniels, Joseph A Lasky, Andrew H Limper, et al.
Pageof 24

Showing results (101-110 of 231) with videos related to

Sort By:
Pageof 24
Drugs in R&D|April 29, 2022
Preclinical and Toxicology Studies of BRD5529, a Selective Inhibitor of CARD9Theodore J Kottom, Kyle Schaefbauer, Eva M Carmona, et al.
Infection and Immunity|April 29, 2015
Evidence for Proinflammatory β-1,6 Glucans in the Pneumocystis carinii Cell WallTheodore J Kottom, Deanne M Hebrink, Paige E Jenson, et al.
Infection and Immunity|October 24, 2003
Lung epithelial cells and extracellular matrix components induce expression of Pneumocystis carinii STE20, a gene complementing the mating and pseudohyphal growth defects of STE20 mutant yeastTheodore J Kottom, Julia R Köhler, Charles F Thomas, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 1, 2015
β-Glucan-Activated Human B Lymphocytes Participate in Innate Immune Responses by Releasing Proinflammatory Cytokines and Stimulating Neutrophil ChemotaxisMohamed F Ali, Christopher B Driscoll, Paula R Walters, et al.
Annals of the American Thoracic Society|January 19, 2021
Adoption of the Antifibrotic Medications Pirfenidone and Nintedanib for Patients with Idiopathic Pulmonary FibrosisTimothy M Dempsey, Stephanie Payne, Lindsey Sangaralingham, et al.
Infection and Immunity|March 26, 2003
Surfactant protein D-mediated aggregation of Pneumocystis carinii impairs phagocytosis by alveolar macrophagesSuk-Joong Yong, Zvezdana Vuk-Pavlovic, Joseph E Standing, et al.
American Journal of Respiratory and Critical Care Medicine|June 1, 2019
Clinical Effectiveness of Antifibrotic Medications for Idiopathic Pulmonary FibrosisTimothy M Dempsey, Lindsey R Sangaralingham, Xiaoxi Yao, et al.
American Journal of Respiratory Cell and Molecular Biology|September 16, 2016
Characterization of N-Acetylglucosamine Biosynthesis in Pneumocystis species. A New Potential Target for TherapyTheodore J Kottom, Deanne M Hebrink, Paige E Jenson, et al.
International Journal of Dermatology|March 25, 2016
Pneumocystis jiroveci pneumonia in patients treated with systemic immunosuppressive agents for dermatologic conditions: a systematic review with recommendations for prophylaxisTania M Gonzalez Santiago, David A Wetter, Amer N Kalaaji, et al.
American Journal of Respiratory and Critical Care Medicine|December 17, 2009
Imatinib treatment for idiopathic pulmonary fibrosis: Randomized placebo-controlled trial resultsCraig E Daniels, Joseph A Lasky, Andrew H Limper, et al.
Pageof 24